Tag: regional industrial ecosystem

  • The Challenge of Capacity

    The rise of Asia as a force to be reckoned with in large scale manufacturing of critical components like batteries, solar panels, pharmaceuticals, chemicals, and semiconductors has left US and European governments seeking to catch up with a bit of a dilemma.

    These activities largely moved to Asia because financially-motivated management teams in the West (correctly) recognized that:

    • they were low return in a conventional financial sense (require tremendous investment and maintenance)
    • most of these had a heavy labor component (and higher wages in the US/European meant US/European firms were at a cost disadvantage)
    • these activities tend to benefit from economies of scale and regional industrial ecosystems, so it makes sense for an industry to have fewer and larger suppliers
    • much of the value was concentrated in design and customer relationship, activities the Western companies would retain

    What the companies failed to take into account was the speed at which Asian companies like WuXi, TSMC, Samsung, LG, CATL, Trina, Tongwei, and many others would consolidate (usually with government support), ultimately “graduating” into dominant positions with real market leverage and with the profitability to invest into the higher value activities that were previously the sole domain of Western industry.

    Now, scrambling to reposition themselves closer to the forefront in some of these critical industries, these governments have tried to kickstart domestic efforts, only to face the economic realities that led to the outsourcing to begin with.

    Northvolt, a major European effort to produce advanced batteries in Europe, is one example of this. Despite raising tremendous private capital and securing European government support, the company filed for bankruptcy a few days ago.

    While much hand-wringing is happening in climate-tech circles, I take a different view: this should really not come as a surprise. Battery manufacturing (like semiconductor, solar, pharmaceutical, etc) requires huge amounts of capital and painstaking trial-and-error to perfect operations, just to produce products that are steadily dropping in price over the long-term. It’s fundamentally a difficult and not-very-rewarding endeavor. And it’s for that reason that the West “gave up” on these years ago.

    But if US and European industrial policy is to be taken seriously here, the respective governments need to internalize that reality and be committed for the long haul. The idea that what these Asian companies are doing is “easily replicated” is simply not true, and the question is not if but when will the next recipient of government support fall into dire straits.


  • Biopharma scrambling to handle Biosecure Act

    Strong regional industrial ecosystems like Silicon Valley (tech), Boston (life science), and Taiwan (semiconductors) are fascinating. Their creation is rare and requires local talent, easy access to supply chains and distribution, academic & government support, business success, and a good amount of luck.

    But, once set in place, they can be remarkably difficult to unseat. Take the semiconductor industry as an example. It’s geopolitical importance has directed billions of dollars towards re-creating a domestic US industry. But, it faces an uphill climb. After all, it’s not only a question of recreating the semiconductor manufacturing factories that have gone overseas, but also:

    • the advanced and low-cost packaging technologies and vendors that are largely based in Asia
    • the engineering and technician talent that is no longer really in the US
    • the ecosystem of contractors and service firms that know exactly how to maintain the facilities and equipment
    • the supply chain for advanced chemicals and specialized parts that make the process technology work
    • the board manufacturers and ODMs/EMSs who do much of the actual work post-chip production that are also concentrated in Asia

    A similar thing has happened in the life sciences CDMO (contract development and manufacturing organization) space. In much the same way that Western companies largely outsourced semiconductor manufacturing to Asia, Western biopharma companies outsourced much of their core drug R&D and manufacturing to Chinese companies like WuXi AppTec and WuXi Biologics. This has resulted in a concentration of talent and an ecosystem of talent and suppliers there that would be difficult to supplant.

    Enter the BIOSECURE Act, a bill being discussed in the House with a strong possibility of becoming a law. It prohibits the US government from working with companies that obtain technology from Chinese biotechnology companies of concern (including WuXi AppTec and WuXi Biologics, among others). This is causing the biopharma industry significant anxiety as they are forced to find (and potentially fund) an alternative CDMO ecosystem that currently does not exist at the level of scale and quality as it does with WuXi.